Rates of ventricular tachycardia, sudden cardiac death and all-cause mortality among postpartum patients in the 6 months immediately postpartum across the 5 participating provinces (2004–2017), by current use of domperidone
| Variable | Incidence rate (95% CI)* | Crude rate ratio (95% CI) | Crude rate difference (95% CI)* |
|---|---|---|---|
| Composite of VT or sudden cardiac death | |||
| Current domperidone use | 0.74 (0.19 to 2.97) | 2.01 (0.47 to 8.60) | 0.37 (−0.67 to 1.41) |
| No current domperidone use | 0.37 (0.24 to 0.57) | 1.00 (Ref.) | 0.00 (Ref.) |
| VT | |||
| Current domperidone use | 0.74 (0.19 to 2.97) | 3.66 (0.81 to 16.49) | 0.54 (−0.50 to 1.57) |
| No current domperidone use | 0.20 (0.11 to 0.37) | 1.00 (Ref.) | 0.00 (Ref.) |
| Sudden cardiac death | |||
| Current domperidone use | 0.00 (0.00 to 0.00) | — | −0.18 (−0.30 to −0.07) |
| No current domperidone use | 0.18 (0.10 to 0.34) | 1.00 (Ref.) | 0.00 (Ref.) |
| All-cause mortality | |||
| Current domperidone use | 1.11 (0.36 to 3.45) | 0.37 (0.12 to 1.15) | −1.93 (−3.28 to −0.59) |
| No current domperidone use | 3.05 (2.61 to 3.55) | 1.00 (Ref.) | 0.00 (Ref.) |
Note: CI = confidence interval, Ref. = reference, VT = ventricular tachycardia.
↵* Incidence rate and rate difference are expressed as event per 10 000 person-years. Event totals by treatment group are not reported owing to the presence of small cells (counts < 6).